News 2016

OBI Pharma Awarded Level-A Recognition for TIPS Management

OBI Pharma, Taiwan (4174) announced that it has been awarded a “Level-A” rating by  auditors from the government-sponsored TIPS (Taiwan Intellectual Property Management System) project, in recognition of the quality …

OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

OBI Pharma, Taiwan (4174) announced that it has been granted Taiwan and Australian patents protecting OBI-833, its new cancer vaccine comprised of the Globo H hexasaccharide (Globo H) antigen conjugated …

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

OBI Pharma is pleased to provide video highlights from the successful company-sponsored symposium that took place at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting in Copenhagen, Denmark, …

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

In response to Next Magazine’s continuous and malicious publication of misleading stories against our client, OBI Pharma Inc. (hereinafter referred to as “OBI”), we, Formosan Brothers, Attorneys-at-Law, and EY Taiwan, …

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Experts Examine the Future of Active Immunotherapy in Oncology and the potential role of Adagloxad Simolenin (OBI-822) TAIPEI, TAIWAN, September 6, 2016 – OBI Pharma, Inc., a Taiwan biotech company …

Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”

Some media have reported on Dr. Michael Chang, the Chairman of OBI Pharma, Inc. (4174.TWO, hereinafter referred to as OBI) and the former president of the Academia Sinica, Dr. Chi-Huey …

Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

OBI Pharma today announced that Dr. Nathan Chen has resigned his post as Chief Medical Officer for personal reasons, effective from August 10, 2016. Dr. Chen continues to be deeply …

Quick Takes on Promising New Approaches to Treating Breast Cancer

ASCO KOL interviews: Dr. Hope Rugo/Dr. James C. Paulson

OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

Results from Phase II/III Clinical Trials Show Improvement in Subset of Patients who Developed an Immune Response to Vaccination TAIPEI, TAIWAN, June 04, 2016 — OBI Pharma, Inc., a Taiwan …